Evotec AG | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
96,616.00
89,239.00
134,354.00
126,270.00
91,156.00
149,449
Total Accounts Receivable
18,210.00
26,146.00
22,190.00
29,828.00
53,016.00
81,411
Inventories
2,358.00
3,111.00
3,133.00
4,305.00
9,017.00
5,660
Other Current Assets
5,342.00
6,804.00
7,263.00
8,832.00
27,063.00
13,249
Total Current Assets
122,526.00
125,300.00
166,940.00
169,235.00
180,252.00
249,769
Net Property, Plant & Equipment
24,239.00
24,045.00
38,334.00
43,018.00
74,662.00
90,519
Total Investments and Advances
87.00
91.00
80.00
3,968.00
22,141.00
28,990
Long-Term Note Receivable
-
-
2,068.00
-
-
-
Intangible Assets
79,962.00
75,025.00
70,802.00
118,955.00
355,211.00
343,780
Other Assets
566.00
139.00
1,502.00
8,469.00
15,769.00
15,496
Total Assets
227,380.00
236,096.00
299,151.00
354,107.00
682,486.00
785,413
ST Debt & Current Portion LT Debt
17,227.00
13,363.00
14,213.00
21,603.00
168,468.00
Accounts Payable
6,653.00
9,450.00
12,171.00
11,997.00
26,078.00
Income Tax Payable
741.00
1,046.00
232.00
802.00
2,033.00
Other Current Liabilities
14,332.00
9,209.00
29,784.00
38,988.00
49,196.00
Total Current Liabilities
38,953.00
33,068.00
56,400.00
73,390.00
245,775.00
Long-Term Debt
14.00
8,186.00
8,730.00
7,224.00
21,460.00
Provision for Risks & Charges
18,586.00
17,957.00
27,342.00
14,801.00
15,366.00
Deferred Taxes
1,245.00
1,583.00
7,274.00
7,606.00
4,266.00
Other Liabilities
9,615.00
5,423.00
7,434.00
41,900.00
29,421.00
Total Liabilities
68,413.00
77,713.00
112,057.00
140,171.00
350,739.00
Common Equity (Total)
158,967.00
158,383.00
185,502.00
213,035.00
330,755.00
Total Shareholders' Equity
158,967.00
158,383.00
185,502.00
213,035.00
330,755.00
Total Equity
158,967.00
158,383.00
187,094.00
213,936.00
331,747.00
Liabilities & Shareholders' Equity
227,380.00
236,096.00
299,151.00
354,107.00
682,486.00
Accumulated Minority Interest
-
-
1,592.00
901.00
992.00

About Evotec

View Profile
Address
Manfred Eigen Campus
Hamburg Hamburg 22419
Germany
Employees -
Website http://evotec.com
Updated 07/08/2019
Evotec AG engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the EVT Execute and EVT Innovate segments. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties.